Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 7.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 633,864 shares of the biotechnology company's stock after selling 48,460 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.31% of BioCryst Pharmaceuticals worth $4,767,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in BCRX. Fisher Asset Management LLC grew its position in shares of BioCryst Pharmaceuticals by 16.9% during the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after buying an additional 481,359 shares in the last quarter. BNP Paribas Financial Markets boosted its position in BioCryst Pharmaceuticals by 472.0% during the third quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company's stock valued at $3,776,000 after purchasing an additional 409,938 shares in the last quarter. Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals by 1,058.1% during the third quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock valued at $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Cinctive Capital Management LP bought a new stake in BioCryst Pharmaceuticals during the third quarter valued at about $2,082,000. Finally, Two Sigma Advisers LP boosted its position in BioCryst Pharmaceuticals by 13.6% during the third quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after purchasing an additional 261,500 shares in the last quarter. Institutional investors own 85.88% of the company's stock.
BioCryst Pharmaceuticals Trading Up 0.8 %
Shares of BCRX traded up $0.06 during mid-day trading on Thursday, hitting $7.69. 2,948,845 shares of the company's stock were exchanged, compared to its average volume of 3,306,191. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The firm has a market capitalization of $1.61 billion, a P/E ratio of -12.61 and a beta of 1.85. The business's 50 day moving average is $8.12 and its two-hundred day moving average is $7.83.
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. The firm's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS. On average, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.
Wall Street Analyst Weigh In
BCRX has been the subject of several research analyst reports. Needham & Company LLC raised their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, January 13th. Evercore ISI increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price objective for the company. JMP Securities reiterated a "market outperform" rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $15.57.
View Our Latest Stock Analysis on BCRX
BioCryst Pharmaceuticals Profile
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Read More
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
